Primary prevention

Approaches for primary prevention include pharmacological prophylaxis (e.g., low molecular weight heparin [LMWH], unfractionated heparin, direct-acting oral anticoagulants, fondaparinux) and mechanical thromboprophylaxis (e.g., graduated compression stockings, intermittent pneumatic compression). [ Cochrane Clinical Answers logo ] ​​​ The efficacy of inferior vena cava filters for the prevention of PE remains unclear.[68][69][70]​​​​ Recent studies have found that primary prevention improves with a multi-faceted approach including computer alerts.[71]

The UK National Institute for Health and Care Excellence (NICE) gives specific recommendations for the primary prevention of venous thromboembolism (VTE) in several patient populations.[72]

Surgical patients

Interventions for people having abdominal surgery:[72]

  • Offer VTE prophylaxis to people undergoing abdominal (gastrointestinal, gynaecological, urological) surgery who are at increased risk of VTE.

  • Start mechanical VTE prophylaxis on admission for people undergoing abdominal surgery, with either anti-embolism stockings or intermittent pneumatic compression.

  • Add pharmacological VTE prophylaxis for ≥7 days for people undergoing abdominal surgery whose risk of VTE outweighs their risk of bleeding. This can be done with either LMWH or fondaparinux sodium.

​Interventions for people having thoracic surgery:[72]

  • Consider VTE prophylaxis for people undergoing thoracic surgery who are at increased risk of VTE.

  • Start mechanical VTE prophylaxis on admission for people undergoing thoracic surgery, with either anti-embolism stockings or intermittent pneumatic compression.

  • Consider adding pharmacological VTE prophylaxis for ≥7 days for people undergoing thoracic surgery whose risk of VTE outweighs their risk of bleeding. Use LMWH as first-line or, if contraindicated, use fondaparinux sodium.

Interventions for people having head and neck surgery:[72]

  • Consider pharmacological VTE prophylaxis with LMWH for ≥7 days for people undergoing oral or maxillofacial surgery or ear, nose, or throat (ENT) surgery whose risk of VTE outweighs their risk of bleeding.

  • Consider mechanical VTE prophylaxis on admission for people undergoing oral or maxillofacial surgery or ENT surgery who are at increased risk of VTE and high risk of bleeding. This can be done with either anti-embolism stockings or intermittent pneumatic compression.

Interventions for people having cardiac surgery:[72]

  • Consider mechanical VTE prophylaxis on admission for people who are undergoing cardiac surgery who are at increased risk of VTE. Choose either anti-embolism stockings or intermittent pneumatic compression.

  • Consider adding pharmacological VTE prophylaxis for ≥7 days for people undergoing cardiac surgery who are not having other anticoagulation therapy. Use LMWH as first-line or, if contraindicated, use fondaparinux sodium.

NICE also makes recommendations for patients undergoing bariatric surgery, orthopaedic surgery, spinal or cranial surgery, and vascular surgery.[72]​ NICE also recommends that patients are advised to stop oestrogen-containing oral contraceptives or hormone replacement therapy 4 weeks before elective surgery and that advice on alternative methods should be provided.[72]

Acutely ill medical patients:[72]

  • Offer pharmacological VTE prophylaxis for ≥7 days to acutely ill medical patients whose risk of VTE outweighs their risk of bleeding. Use LMWH as first-line or, if contraindicated, use fondaparinux sodium.

Acute stroke patients:[72]​​​​

  • Do not offer anti-embolism stockings for VTE prophylaxis.

  • Consider intermittent pneumatic compression for people admitted with acute stroke who are immobile (and start within 3 days of acute stroke).

Pregnancy

LMWH is recommended for the prevention of VTE in pregnant women, and in women who gave birth or had a miscarriage or termination of pregnancy in the past 6 weeks who are admitted to hospital and whose risk of VTE outweighs their risk of bleeding. This does not apply to those in active labour where VTE prophylaxis should not be started or should be stopped.[39][72]

People with cancer

Routine pharmacological prophylaxis is not recommended for outpatients with cancer who have no additional risk factors for VTE.[72][73]​​​​ There are some circumstances where VTE prophylaxis should be considered, such as people receiving chemotherapy for myeloma or pancreatic cancer; further details on this are given in the NICE guidance.[72]

Long-distance travel

The British Society for Haematology does not recommend the use of graduated compression stockings or pharmacological thrombophylaxis in long-distance (>4 hours) travellers. Those travellers at increased risk of VTE (e.g., recent surgery or trauma, active malignancy, pregnancy, severe immobility, previous unprovoked VTE and no longer on anticoagulants) should consider using pharmacological thromboprophylaxis with or without graduated compression stockings for travel more than 4 hours.[36]​ Compression stockings should be properly fitted, below-knee, and graduated, and provide 15 to 30 mmHg of pressure at the ankle during travel. During travel, people at increased risk of VTE should move or walk about frequently, exercise their calf muscles, and sit in an aisle seat (if possible).

Secondary prevention

Continue anticoagulation for at least 3 months for all patients with PE. Review all patients at 3 months as a minimum.[67][218]

  • Discuss with a senior colleague whether to continue anticoagulation beyond 3 months. This decision should weigh up the individual patient’s risk of recurrence of PE versus bleeding risk. Discuss the risks and benefits of long-term anticoagulation with the patient, and take their preferences into account.[76]

  • In general, anticoagulation can usually stopped after 3 months (or 3 to 6 months for people with active cancer) if the PE was provoked, as long as the transient risk factor is no longer present and the clinical course has been uncomplicated. Anticoagulation is usually continued for longer if the PE was unprovoked.[76]

    • A provoked PE is one associated with a transient risk factor that was present in the 3 months prior to the PE.[76]

    • An unprovoked PE is a PE in a patient who had no pre-existing, transient provoking risk factor in the prior 3 months.[76]

    • Provoking risk factors include: surgery; trauma; significant immobility (bedbound, unable to walk unaided, or likely to spend a substantial proportion of the day in bed or in a chair); pregnancy or puerperium; use of oral contraceptive/hormone replacement therapy).[76]

Annually reassess the risks/benefits of continuing anticoagulation, as well as the patient's general health and treatment preferences, in all patients receiving extended treatment beyond 3 months.[67][76][166]​​

In general, offer continued treatment with the anticoagulant used in the acute phase if it is well tolerated.[76]

  • If the patient has been started on a DOAC other than apixaban and this is not well tolerated, or the clinical situation or patient preference has changed, consider switching to apixaban if the patient does not have abnormal kidney function, active cancer, established triple positive antiphospholipid syndrome, or extreme body weight (<50 kg or >120 kg).[76]

  • In patients taking apixaban or rivaroxaban who need ongoing anticoagulation for >6 months, it is becoming common practice to consider a dose reduction.[241]

  • In pregnant patients, continue LMWH for the remainder of the pregnancy and for at least 6 weeks postnatally and until at least 3 months of treatment has been given in total.[242]

    • In the last month of pregnancy, or sooner if delivery appears imminent, women receiving either therapeutic or prophylactic anticoagulation may be converted from LMWH to UFH, which has a shorter half-life, is easy to monitor, and is readily reversed by protamine.[39][187]

Consider aspirin if the patient refuses or is unable to tolerate any form of oral anticoagulant.[76]

Use of this content is subject to our disclaimer